Neoplasms, Metastatic Neuroendocrine Tumour - France

Trial Radar AI Trial Candidate or Patient Patient Caregiver Healthcare Pro Biotech Pro Biotech Investor Researcher Other
	Showing clinical trials for Neoplasms, Metastatic Neuroendocrine Tumour matching location: France. I can help you find clinical trials in specific locations and provide insights on health conditions and treatments. With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

Showing clinical trials for Neoplasms, Metastatic Neuroendocrine Tumour matching location: France.

I can help you find clinical trials in specific locations and provide insights on health conditions and treatments.

With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

Study Title	Status
Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region. (AURA-RIV-TNE) NCT06043193	Recruiting
Post-Authorization Long-Term Safety Study of LUTATHERA (SALUS) NCT03691064	Active, not recruiting
TARGETed Therapy Drug MONITOring in DIGestive Oncology (TARGETMONITO) NCT05443087	Recruiting
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. NCT06379217	Active, not recruiting
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary (FOLFIRINEC) NCT04325425	Recruiting
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) NCT03093116	Recruiting
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064	Recruiting
Pharmaceutical Management in Targeted Radioligand Therapy (PharmTRT) NCT07389512	Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680	Not yet recruiting
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors NCT06781983	Recruiting
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) NCT06333314	Recruiting
Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) NCT07016230	Recruiting
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers (DP-PAN-CANCER) NCT06967961	Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) NCT05592626	Recruiting
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy (IMMUNOPET2) NCT04272658	Recruiting
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1 (HELIOPREDICT) NCT05856565	Recruiting
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) NCT05282901	Active, not recruiting
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy (TEP-ANTI-PD1) NCT03888950	Recruiting
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas NCT05415072	Active, not recruiting
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma NCT05987332	Active, not recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. NCT05727904	Recruiting
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) NCT05155254	Active, not recruiting
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma NCT04674683	Active, not recruiting
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1) NCT05688280	Active, not recruiting
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors NCT03645928	Recruiting
Dabrafenib and/or Trametinib Rollover Study NCT03340506	Recruiting
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) NCT01896479	Active, not recruitingResults Posted
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478	Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors NCT04913285	Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) NCT06346067	Active, not recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma NCT05352672	Active, not recruiting
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) NCT02568267	Active, not recruiting
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) NCT03915678	Recruiting
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) NCT04074096	Active, not recruiting
Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors (mela-quantif) NCT05649683	Recruiting
Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients (COLEMAN) NCT05029791	Recruiting
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma NCT04657991	Active, not recruiting
Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021 (IMM) NCT07302607	Recruiting
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (MOIO) NCT05078047	Recruiting
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) NCT05061134	Active, not recruitingResults Posted
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma NCT01979523	Active, not recruitingResults Posted
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma NCT06054555	Active, not recruiting
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) NCT05625399	Active, not recruiting
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma NCT04417621	Active, not recruiting
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047) NCT03470922	Active, not recruitingResults Posted
Neoadjuvant Darovasertib in Primary Uveal Melanoma NCT07015190	Recruiting
Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary (MelBase) NCT02828202	Recruiting
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) NCT03235245	Active, not recruiting
Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma (SPEBINI) NCT06774989	Recruiting
Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM) NCT06246149	Recruiting

Clinical Trial Radar

Phase

Type

Study Type

Age Group

Biological Sex